Search results
Showing 16 to 30 of 58 results for durvalumab
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
In development Reference number: GID-TA11405 Expected publication date: TBC
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
In development Reference number: GID-TA11232 Expected publication date: 08 April 2026
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]
Awaiting development Reference number: GID-TA11076 Expected publication date: TBC
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-NG10404 Expected publication date: TBC
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued Reference number: GID-TA10394
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
Discontinued Reference number: GID-TA10633